“We continue to make progress in 2023 with zelnecirnon in inflammatory diseases and with tivumecirnon in oncology,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “We anticipate reporting top-line data from our Phase 2b trial of zelnecirnon in atopic dermatitis in mid-2024 and we are pleased with how the trial is enrolling. Furthermore, we have made good progress in enrolling our Phase 2a trial in asthma. Earlier this month, we presented exciting Phase 2 data for tivumecirnon in combination with pembrolizumab in checkpoint-naive non-small cell lung cancer at SITC. Our current cash balance remains strong and we expect it to support our planned operations through mid-2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RAPT:
- RAPT Therapeutics Reports Third Quarter 2023 Financial Results
- Rapt Therapeutics reports ‘positive’ data from Phase 2 FLX475 combo trial
- RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC